Pelthos Therapeutics Inc. is focused on commercializing safe and effective therapeutic products for patients with unmet treatment needs.
Their flagship drug, Zelsuvmi, launched in July 2025, targets the treatment of Molluscum contagiosum with a unique at-home treatment approach.
With a market potential worth over $20 billion, Pelthos Therapeutics aims to address the needs of the 16.7 million individuals affected by MC in the U.S.
Commercial Launch Success
Zelsuvmi's successful commercial launch in July 2025 marks a significant milestone for Pelthos Therapeutics in addressing the unmet needs of patients with Molluscum contagiosum.
Experienced Management Team
Pelthos Therapeutics boasts a management team with over 20 successful prior drug launches, positioning the company for continued growth and innovation in the bio-pharmaceutical industry.
Financial Highlights
With a current peak Net Revenue forecast of $175 million per annum by 2028, Pelthos Therapeutics shows promising financial growth prospects in the pharmaceutical market.
- Pelthos Therapeutics' focus on innovative therapeutic products presents a potential breakthrough in addressing unmet medical needs for patients with Molluscum contagiosum.
- The launch of Zelsuvmi as the first at-home treatment option for MC signifies a shift in the traditional treatment approach, offering convenience and effectiveness to patients.
In conclusion, Pelthos Therapeutics Inc. stands at the forefront of bio-pharmaceutical innovation with the successful launch of Zelsuvmi and a strong commitment to addressing unmet medical need